Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JUMBO-TIMI 26: Prasugrel vs Clopidogrel in PCI
NCT00059215Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2003
- Primary completion
- Jan 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of prasugrel in coronary artery disease (CAD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With Non-coronary Artery Bypass Graft (Non-CABG) Thrombolysis in Myocardial Infarction (TIMI) Major or Minor Bleeding Events at 30 days. Started Apr 2003; status: completed.
02
Drugs
prasugrel
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00059215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00059215.